The latest from Sequence Bio

An updated brand for the future of Sequence Bio

Sequence Bio named one of Canada’s Top Small & Medium employers for 2026

Taking on inherited disease, together: Sequence Bio launches multi-disease genetic research study in Newfoundland and Labrador

Sequence Bio Named one of Atlantic Canada’s Best Places to Work for 2026

Sequence Bio launches genetics study of idiopathic pulmonary fibrosis

Sequence Bio launches genetics study of familial ovarian cancer

Sequence Bio enters into a Benefits and Royalty Agreement with the Government of Newfoundland & Labrador

Sequence Bio Appoints Dr. Tom Barber as Chief Scientific Officer

Sequence Bio and Memorial University collaborate to study the genetics of multiple sclerosis

New study details ancestry and other contributions to the genetic substructure of the Newfoundland and Labrador founder population

Sequence Bio launches genetics study of familial multiple sclerosis

Sequence Bio appoints Lynn Healey as Chief Executive Officer

New study illustrates unique genetic landscape in Newfoundland and Labrador with links to Ireland and England

Sequence Bio announces Discovery Collaboration Agreement with LEO Pharma

Sequence Bio recognized with Women in Tech Advocate Award

Sequence Bio begins search for better, safer medicines and disease treatments with launch of the NL Genome Project.